Insitro Stock
Insitro is revolutionizing pharmaceutical R&D by leveraging machine learning for drug discovery.
About Insitro Stock
Over the past decades, developing drugs has become increasingly more difficult and expensive, leaving many patients with significant unmet need. A constellation of technologies now allows us to construct, perturb, and observe biological model systems in the laboratory, allowing the generation of biomolecular data at unprecedented breadth and scale. At the same time, the tools of data science and machine learning are now solving problems previously thought to be decades away from solution. We aim to combine these technologies to develop a new approach to drug development that might help us cure more people, sooner, and at a much lower cost.
Funding History
| May 2018 | $0 |
|---|
Management
Founder & CEO
Daphne Koller
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Insitro or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
